T Cell bispecific antibody
A concept being tested in cancer immunotherapy is a T cell bispecific antibody, which could physically link a cancer cell to an immune cell. This would lead to activation of the patient’s own immune system to attack cancer. With the ability to engineer this highly complex platform, Roche scientists hope that this type of antibody will have several advantageous properties. In addition to engaging T cells to recognize and destroy tumours, Roche’s molecules have a long circulatory half-life, reduced non-specific activation of the immune system due to the ability to directly link cancer cells with T cells, and the potential ability to distinguish between tumour cells overexpressing a target and normal cells that may express low levels of the same target.